Number of eligible individuals: CDEC talked about the uncertainty in the quantity of clients with reasonably severe to serious hemophilia B in Canada qualified for etranacogene dezaparvovec. Scientific professionals consulted by CADTH indicated that some people who're categorized as getting mild or reasonable illness might have a severe bleeding phenotype, https://hemgenix93715.newsbloger.com/36464558/not-known-factual-statements-about-hemgenix